Risultati di ricerca - Portale di modelli di dati medici (MDM-Portal)

Pancreatic Cancer NCT00058149 Quality of Life - Brief Pain Inventory - 2031356v3.0 - Brief Pain Inventory

- 9/1/15 - 1 modulo, 2 itemgroups, 23 elementi, 1 linguaggio

Itemgroups: Header, CCRR MODULE

Brief Pain Inventory A Phase III, Randomized Study of Gemcitabine (Fixed-Dose Rate Infusion) and Oxaliplatin (NSC 266046) Versus Gemcitabine (Fixed-Dose Rate Infusion) Versus Gemcitabine (30-Minute Infusion) in Pancreatic Carcinoma Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=AE65F8E1-704E-30A0-E034-0003BA12F5E7

Pancreatic Symptom Index NCT00058149

- 20/9/21 - 1 modulo, 3 itemgroups, 22 elementi, 1 linguaggio

Itemgroups: ECOG clinical trial administrative data, Symptom assessment, CCRR MODULE

Pancreatic Symptom Index NCT00058149 A Phase III, Randomized Study of Gemcitabine (Fixed-Dose Rate Infusion) and Oxaliplatin (NSC 266046) Versus Gemcitabine (Fixed-Dose Rate Infusion) Versus Gemcitabine (30-Minute Infusion) in Pancreatic Carcinoma Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=A65D73CD-6E86-428A-E034-0003BA0B1A09

Pancreatic Cancer NCT00088894 - EQ-5D FORM Pancreatic Cancer CALGB NCT00088894

- 2/7/17 - 1 modulo, 2 itemgroups, 13 elementi, 1 linguaggio

Itemgroups: Header, EQ-5D

CALGB: EQ-5D FORM Gemcitabine With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=D602C703-1CB1-3D8F-E034-0003BA12F5E7

Visit 7 / Early Termination Diab-MedSat [QS_3] NCT01117584

- 20/9/21 - 1 modulo, 9 itemgroups, 24 elementi, 1 linguaggio

Itemgroups: General Information, 1. Over the past two weeks, how bothered have you been by..., 2. Over the past two weeks, how bothered have you been by any of the following due to your diabetes medication(s)?, 3. Over the past past two weeks, how dissatisfied or satisfied have you been with the ability of your diabetes medication(s) to...., 4. Overall, over the past two weeks, how dissatisfied or satisfied have you been with...., 5. Thinking about your diabetes medication(s) over the past two weeks...., 6. Over the past two weeks, how often has taking your diabetes medication(s) as prescribed interfered with your ability to..., 7. Overall, thinking about each of the aspects of your diabetes medication(s) as mentioned above, how dissatisfied or satisfied have you been with ...., 8. Overall, based on your current experiences with your diabetes medications...

NCT01117584 Astellas Phase 2b, Double-Blind, Randomized, Multicenter, Parallel Group, Placebo-Controlled, Dose-Finding Study to Evaluate the Efficacy, Safety and Tolerability of a 12- Week Treatment with ASP1941 in Combination with Metformin in Patients with Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin Alone.

Visit 9 Follow-up Diab-MedSat [QS_3] NCT01117584

- 20/9/21 - 1 modulo, 9 itemgroups, 24 elementi, 1 linguaggio

Itemgroups: General Information, 1. Over the past two weeks, how bothered have you been by..., 2. Over the past two weeks, how bothered have you been by any of the following due to your diabetes medication(s)?, 3. Over the past past two weeks, how dissatisfied or satisfied have you been with the ability of your diabetes medication(s) to...., 4. Overall, over the past two weeks, how dissatisfied or satisfied have you been with...., 5. Thinking about your diabetes medication(s) over the past two weeks...., 6. Over the past two weeks, how often has taking your diabetes medication(s) as prescribed interfered with your ability to..., 7. Overall, thinking about each of the aspects of your diabetes medication(s) as mentioned above, how dissatisfied or satisfied have you been with ...., 8. Overall, based on your current experiences with your diabetes medications...

NCT01117584 Astellas Phase 2b, Double-Blind, Randomized, Multicenter, Parallel Group, Placebo-Controlled, Dose-Finding Study to Evaluate the Efficacy, Safety and Tolerability of a 12- Week Treatment with ASP1941 in Combination with Metformin in Patients with Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin Alone.

Visit 2 Baseline Diab-MedSat [QS_3] NCT01117584

- 20/9/21 - 1 modulo, 9 itemgroups, 24 elementi, 1 linguaggio

Itemgroups: General Information, 1. Over the past two weeks, how bothered have you been by..., 2. Over the past two weeks, how bothered have you been by any of the following due to your diabetes medication(s)?, 3. Over the past past two weeks, how dissatisfied or satisfied have you been with the ability of your diabetes medication(s) to...., 4. Overall, over the past two weeks, how dissatisfied or satisfied have you been with...., 5. Thinking about your diabetes medication(s) over the past two weeks...., 6. Over the past two weeks, how often has taking your diabetes medication(s) as prescribed interfered with your ability to..., 7. Overall, thinking about each of the aspects of your diabetes medication(s) as mentioned above, how dissatisfied or satisfied have you been with ...., 8. Overall, based on your current experiences with your diabetes medications...

NCT01117584 Astellas Phase 2b, Double-Blind, Randomized, Multicenter, Parallel Group, Placebo-Controlled, Dose-Finding Study to Evaluate the Efficacy, Safety and Tolerability of a 12- Week Treatment with ASP1941 in Combination with Metformin in Patients with Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin Alone.